Given the profound adverse implications of TP53 mutations in myeloid neoplasms, there is an urgent need for targeted therapies to treat TP53-mutant leukemias and prevent the progression of these high-risk malignancies. The gene discussed is TP53; the disease is myeloid neoplasm.